SCHEMBL5352923

SCHEMBL5352923

COCOC(CCNS(=O)(=O)c1cccc(-c2cc(C(C)=O)c(NC(=O)OC(C)(C)C)s2)c1)c1ccc(F)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.34
NPSR1 Q6W5P4 2/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
ALDH1A1 P00352 3/20 0.32
HPGD P15428 2/20 0.32
KDM4E B2RXH2 2/20 0.32
TP53 P04637 1/20 0.32
THRB P10828 1/20 0.32
RORC P51449 5/20 0.32
MEN1 O00255 1/20 0.32
IKBKB O14920 1/20 0.32
JAK2 O60674 1/20 0.32
EIF2AK2 P19525 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
LMNA P02545 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5358765 0.78 SMN1; SMN2 (0.34) RORCLMNA
SCHEMBL5358155 0.78 RORC (0.33) RORC
SCHEMBL5348115 0.77 RORC (0.33) RORC
SCHEMBL5359290 0.76 CYP3A4 (0.34) NPSR1CA1ALDH1A1HPGDTP53
SCHEMBL5350424 0.68 RORC (0.36) RORCMEN1KMT2A
SCHEMBL5430509 0.68 IKBKB (0.52) NPSR1ALDH1A1HPGDKDM4ETP53
SCHEMBL5358758 0.66 MAPT (0.36) ALDH1A1RORCMEN1KMT2ALMNA
SCHEMBL5358993 0.65 KCNH2 (0.41) POLBALDH1A1MEN1KMT2ALMNA
SCHEMBL5352377 0.65 SMN1; SMN2 (0.39) NPSR1ALDH1A1KDM4ETP53MEN1
SCHEMBL5358149 0.65 RORC (0.33) RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 POLB 4113/4885NPSR1 455/4885CA1 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.